Literature DB >> 20103065

Heparin-induced thrombocytopenia in surgical patients.

Sandra Battistelli1, Alberto Genovese, Tommaso Gori.   

Abstract

BACKGROUND: Unfractionated and low-molecular-weight heparin are commonly used in the prevention and therapy of a variety of cardiovascular diseases. Because the major side effects of these drugs are hemorrhagic events, very little attention is paid to another important side effect (ie, heparin-induced thrombocytopenia [HIT]). HIT is an immune-mediated transient prothrombotic state with very severe implications determined by thromboembolic phenomena in both the venous and arterial circulation. DATA SOURCES: A PubMed search from 1995 to 2008 was performed. Pertinent literature was identified and other references retrieved from bibliographic citations of the articles identified on PubMed. Articles related to the pathogenesis, clinical picture, diagnosis and treatment of HIT were reviewed.
CONCLUSIONS: HIT is a potentially fatal but treatable and largely preventable disease. An increased awareness of the signs and symptoms of the disorder is necessary to prevent its potentially devastating complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103065     DOI: 10.1016/j.amjsurg.2009.01.029

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  12 in total

1.  What's new about heparin-induced thrombocytopenia type II.

Authors:  Yasser Sakr
Journal:  Intensive Care Med       Date:  2015-04-23       Impact factor: 17.440

2.  Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.

Authors:  Linda Hoang; Shahidul Islam; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

3.  Design of hydrogels to stabilize and enhance bone morphogenetic protein activity by heparin mimetics.

Authors:  Soyon Kim; Zhong-Kai Cui; Paul Jay Kim; Lawrence Young Jung; Min Lee
Journal:  Acta Biomater       Date:  2018-03-26       Impact factor: 8.947

4.  Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature.

Authors:  Salam Alkindi; Owen P Smith; Helen Enright
Journal:  Sultan Qaboos Univ Med J       Date:  2011-08-15

Review 5.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

6.  Sulfonate Hydrogel-siRNA Conjugate Facilitates Osteogenic Differentiation of Mesenchymal Stem Cells by Controlled Gene Silencing and Activation of BMP Signaling.

Authors:  Soyon Kim; Jiabing Fan; Chung-Sung Lee; Chen Chen; Min Lee
Journal:  ACS Appl Bio Mater       Date:  2021-05-27

7.  Intra-aortic balloon pumping and thrombocytopenia in patients with acute coronary syndrome : Incidence, risk factors, and prognosis.

Authors:  Z Sheng; H Zhao; H Yan; S Jiang; Y Guan; Y Zhang; L Song; C Liu; P Zhou; K Liu; J Liu; Y Tan
Journal:  Herz       Date:  2017-07-19       Impact factor: 1.443

Review 8.  Heparin-induced thrombocytopenia in the ICU: an overview.

Authors:  Yasser Sakr
Journal:  Crit Care       Date:  2011-03-22       Impact factor: 9.097

9.  Stent thrombosis caused by metal allergy complicated by protein S deficiency and heparin-induced thrombocytopenia: a case report and review of the literature.

Authors:  Takao Konishi; Tadashi Yamamoto; Naohiro Funayama; Beni Yamaguchi; Seiichiro Sakurai; Hiroshi Nishihara; Koko Yamazaki; Yusuke Kashiwagi; Yasuki Sasa; Mitsuru Gima; Hideichi Tanaka; Daisuke Hotta; Kenjiro Kikuchi
Journal:  Thromb J       Date:  2015-07-23

Review 10.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis; Amanda Burls
Journal:  Cochrane Database Syst Rev       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.